Vimarsana
Biggest News Aggregation in the World

Page 25 - Blue Chips News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Blue Chips. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Blue Chips Today - Breaking & Trending Today

Vertex Pharmaceuticals Incorporated: Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress - Vimarsana News

Vertex Pharmaceuticals Incorporated: Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - Data continue to demonstrate transformative and durable benefit - Safety profile consistent with busulfan

EQS-Adhoc: Dexus Finance Pty Limited: Sale of 44 Market Street Sydney - Vimarsana News

EQS-Adhoc: Dexus Finance Pty Limited: Sale of 44 Market Street Sydney

EQS-Ad-hoc: Dexus Finance Pty Limited / Key word(s): Disposal/Real Estate Dexus Finance Pty Limited: Sale of 44 Market Street Sydney 09-Jun-2023 / 08:51 CET/CEST Disclosure of an inside information

18th Edition of Information Security Summit Indonesia - Vimarsana News

18th Edition of Information Security Summit Indonesia

Physical Conference on 20th July 2023 JAKARTA, Indonesia, June 9, 2023 - (ACN Newswire) - After successful 17 editions of Information Security Summit, Exito is all set to host another milestone event-

Perfuze Announces Appointment of New Chair of the Board - Vimarsana News

Perfuze Announces Appointment of New Chair of the Board

Perfuze, a medical device company developing next-generation "super-bore" catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami as the new Chair

Wugen, Inc.: Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress - Vimarsana News

Wugen, Inc.: Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- -- WU-CART-007 demonstrated preliminary evidence of anti-leukemic